Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
The aldosterone antagonist spironolactone undergoes extensive and complex biotransformation. For investigation of bioequivalence of 2 oral spironolactone formulations, Spironolacton 50 Heumann and Aldactone 50, the pharmacokinetics and bioequivalence of the parent drug and 2 predominant active metabolites, canrenone and 7 alpha-thiomethylspirolactone, were determined in a 2-way crossover study in 24 young healthy male volunteers after multiple oral dosing of 100 mg once daily. Plasma samples were measured by a newly developed HPLC assay and individual pharmacokinetic parameters of the 3 compounds were calculated by use of noncompartmental techniques. Statistical analysis was performed by ANOVA and nonparametric methods. Spironolactone was rapidly cleared from plasma. Therefore, only Css,max and tss,max were determined. Concerning Css,max bioequivalence was found with 90% classical shortest confidence interval ranging from 80.7-112.4%. The intrasubject variability for Css,max was determined to be 28.1%. Higher and persisting concentrations were observed for the metabolites. For canrenone 90% classical shortest confidence intervals were calculated as 95.4-105.0% for AUCss,tau, as 92.9-105.8% for Css,max, and as 89.1-106.3% for peak trough fluctuation (PTF). In the case of 7 alpha-thiomethylspirolactone the values were 84.2-103.0% for AUCss,tau, 77.0-98.6% for Css,max, and 85.0-100.4% for PTF. For tss,max nonparametric 90% confidence intervals were determined as 0.00 to 1.50 h for spironolactone and canrenone and as -0.50 to 1.00 h for 7 alpha-thiomethylspirolactone. The intraindividual variability was below 30% for all pharmacokinetic parameters in the case of the metabolites. Thus, bioequivalence of the test and the reference formulation can be concluded. The study suggests the inclusion of parent compound and metabolites for bioequivalence testing of spironolactone formulations. Intraindividual subject variability was clearly diminished by investigating bioequivalence under steady-state conditions.
Vergin
H
H
Heuman Pharma GmbH, Nürnberg, Germany.
Mahr
G
G
Metz
R
R
Eichinger
A
A
Nitsche
V
V
Martens
H
H
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D002192:Canrenone / Q000097:blood; D018592:Cross-Over Studies; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics*; D013148:Spironolactone / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency; D013997:Time Factors
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; C046564:7-thiomethylspirolactone; D002192:Canrenone